Related Experiment Video

Updated: Aug 11, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

[PI3K-AKT-mTOR pathway inhibitors]

Alexis Cortot1, Jean-Pierre Armand, Jean-Charles Soria

  • 1Département de médecine, Institut Gustave-Roussy, 39, rue Camille-Desmoulin, 94805 Villejuif.

Bulletin Du Cancer
|February 4, 2006
PubMed

Insights

Molecular targeted agents, including signal transduction inhibitors, offer new anti-cancer strategies. This review focuses on the PI3K-AKT-mTOR pathway and its inhibition in cancers, particularly with mTOR inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Molecular targeted agents are expanding cancer treatment options.
  • Signal transduction inhibitors show promise in anti-cancer therapy.
  • The PI3K-AKT-mTOR pathway is frequently dysregulated in human cancers.

Purpose of the Study:

  • To provide an overview of the PI3K-AKT-mTOR pathway.
  • To discuss the targeting of this pathway in human malignancies.
  • To focus on mechanistic target of rapamycin (mTOR) inhibitors.

Main Methods:

  • Literature review of PI3K-AKT-mTOR pathway.
  • Analysis of targeting strategies in cancer.
  • Review of mTOR inhibitors' role.

Main Results:

  • The PI3K-AKT-mTOR pathway is a critical regulator of cell growth and survival.
  • Alterations in this pathway are common across various cancers.
  • mTOR inhibitors represent a significant therapeutic approach.

Conclusions:

  • Targeting the PI3K-AKT-mTOR pathway is a viable anti-cancer strategy.
  • mTOR inhibitors are a key component of this therapeutic approach.
  • Further research into pathway modulation holds promise for improved cancer treatment.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...